FDA warns Dr. Pena-Hernandez over ineligible subject enrollment and lapsed IRB approval for investigational drugs.
What happened
FDA inspected Dr. Pena-Hernandez’s clinical site from January 9 to January 23, 2023, as part of its Bioresearch Monitoring Program. FDA found that one subject did not meet a protocol inclusion criterion requiring current use of a specified drug but was randomized, and that IRB approval lapsed from December 3, 2021, to January 27, 2022, while study visits and procedures were performed. FDA also said his written responses did not provide enough detail on corrective actions.
What FDA found
Failed to ensure the investigation was conducted according to the investigational plan; a subject was randomized even though records did not show the protocol-required current use of a specified drug.
21 CFR 312.60Failed to ensure an IRB compliant with 21 CFR part 56 reviewed and approved the study; IRB approval lapsed from December 3, 2021, to January 27, 2022, while study visits and procedures occurred.
21 CFR 312.66
What FDA wants
Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations; failure to adequately address the matter may lead to regulatory action.
Who should pay attention
- clinical research sites and investigators
- sponsors and contract research organizations relying on investigator oversight
- IRBs and research compliance teams
This is a summary. Read the original letter on fda.gov.